Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3…
By B. Burtness, Kevin J. Harrington, R. Greil, Denis Soulières, M. Tahara, G. de Castro, A. Psyrri, N. Basté, P. Neupane, A. Bratland and 14 more. The Lancet, 2019
2,572 citations recorded by the source corpus.
BACKGROUND Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. METHODS KEYNOTE-048 was a randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries. Participants were stratified by PD-L1 expression, p16 status, and performance status and randomly allocated (1:1:1) to pembrolizumab alone, pembrolizumab plus a platinum and 5-fluorouracil (pembrolizumab with chemotherapy), or cetuximab plus a platinum and 5-fluorouracil (cetuximab with chemotherapy). Investigators and participants were aware of treatment assignment. Investigators, participants, and representatives of the sponsor were masked to the PD-L1 combined positive score (CPS) results; PD-L1 positivity was not required for study entry. The primary endpoints were overall survival (time from randomisation to death from any cause) and progression-free survival (time from randomisation to radiographically confirmed disease progression or death from any cause, whichever came first) in the intention-to-treat population (all participants randomly allocated to a treatment group). There were 14 primary hypotheses: superiority of pembrolizumab alone and of pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival and progression-free survival in the PD-L1 CPS of 20 or more, CPS of 1 or more, and total populations and non-inferiority (non-inferiority margin: 1·2) of pembrolizumab alone and pembrolizumab with chemotherapy versus cetuximab with chemotherapy for overall survival in the total population. The definitive findings for each hypothesis were obtained when statistical testing was completed for that hypothesis; this occurred at the second interim analysis for 11 hypotheses and at final analysis for three hypotheses. Safety was assessed in the as-treated population (all participants who received at least one dose of allocated treatment). This study is registered at ClinicalTrials.gov, number NCT02358031. FINDINGS Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more. At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]). Pembrolizumab with chemotherapy improved overall survival versus cetuximab with chemotherapy in the total population (13·0 months vs 10·7 months, HR 0·77 [95% CI 0·63-0·93], p=0·0034) at the second interim analysis and in the CPS of 20 or more population (14·7 vs 11·0, 0·60 [0·45-0·82], p=0·0004) and CPS of 1 or more population (13·6 vs 10·4, 0·65 [0·53-0·80], p<0·0001) at final analysis. Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis. At final analysis, grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group, 235 (85%) of 276 in the pembrolizumab with chemotherapy group, and 239 (83%) of 287 in the cetuximab with chemotherapy group. Adverse events led to death in 25 (8%) participants in the pembrolizumab alone group, 32 (12%) in the pembrolizumab with chemotherapy group, and 28 (10%) in the cetuximab with chemotherapy group. INTERPRETATION Based on the observed efficacy and safety, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for recurrent or metastatic HNSCC and pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC. FUNDING Merck Sharp & Dohme.
Subfields: Oncology, Otorhinolaryngology, Surgery
View Paper: https://www.semanticscholar.org/paper/2cd818203e55c19ff6613cf1cac2cbf9ce53b1eb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Acquired Resistance to Immune Checkpoint Inhibitors (2020, background): “We have attempted to infer the rates of acquired resistance based upon available duration of response data among different tumor types (Antonia et al., 2019; Armand et al., 2018; Balar et al., 2018; Burtness et al., 2019; Chen et al., 2019a; Cohen et al., 2019; Fehrenbacher et al., 2018; Fradet et a”
- Immune Checkpoint Inhibitors in Cancer Therapy (2022, background): “A phase III study (KEYNOTE-048) date demonstrated that Pembrolizumab compared to chemotherapy has remarkably improved OS in recurrent/metastatic (R/M) HNSCC patients with PD-L1 combined positive score (CPS) ≥20 and its combinations with chemotherapy was more efficacious compared to chemotherapy in R”
- Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “In contrast, approval by the European Medicines Agency (EMA) is restricted to tumors with CPS ≥ 1 for both Pembrolizumab monotherapy and its combination with chemotherapy or a TPS > 50% in second-line treatment [6].”
- Impact of T Cell Exhaustion and Stroma Senescence on Tumor Cell Biology and Clinical Outcome of Head and Neck Squamous Cell Carcinomas (2024, unknown): “Recently, two anti-PD-1 immune checkpoint inhibitors (ICIs), pembrolizumab and nivolumab, have been approved for the treatment of recurrent and metastatic HNSCC [5] for first-line [6] and second-line treatment either as a monotherapy or in combination with platinum-based chemotherapy [7,8].”
- Unraveling the Role of Tumor-Infiltrating Immune Cells in Head and Neck Squamous Cell Carcinoma: Implications for Antitumor Immune Responses and Immunotherapy (2025, unknown): “Based on these results, pembrolizumab received Food and Drug Administration (FDA) approval as a first-line treatment for R/M HNSCC in patients with PD-L1 CPS ≥ 1 (monotherapy) and CPS 1 (in combination with chemotherapy) [101,105].”
- Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma (2023, unknown): “In fact, immune suppression seems to be a prevalent mechanism of neoplastic expansion in this cancer (6), which explains some of the recent successes in advanced-stage HNSCC with multiple checkpoint blockade agents such as pembrolizumab (7) or nivolumab (8).”